Alumis Envudecitinib Phase 3 Readout: What Traders Need to Know

Alumis (ALMS) is set to release Phase 3 data for Envudecitinib, an oral TYK2 inhibitor for psoriasis, in the coming weeks. The readout will determine whether the drug can compete with Bristol-Myers Squibb's Sotyktu or remain a speculative story.

Shares trade near $12, giving the company a market cap around $500 million. Cash from the last filing funds operations into late 2026, removing near-term financing risk. Five analysts carry a consensus target of $66. The gap between price and target reflects the binary nature of the catalyst ahead.

Bristol-Myers's Sotyktu generated about $350 million in sales in 2024. It is the only approved oral TYK2 inhibitor for the indication. The Seeking Alpha analysis that flagged Envudecitinib as a potential "real deal" argued the drug could be best-in-class due to better selectivity and fewer safety concerns. Phase 2 data showed strong efficacy with a clean safety profile. Phase 3 is the standard that matters.

The trial measures non-inferiority or superiority to Sotyktu on PASI 75 and PASI 90 at 16 weeks. A clear win on efficacy with comparable safety would validate the thesis. A miss, whether from weaker efficacy or unexpected side effects, would likely cut the stock sharply given the single-product pipeline and low valuation.

Liquidity is thin. Average daily volume runs well below $10 million. A binary event creates sharp moves that can punish outsized positions. The stock already carries a discount relative to peers because of the uncertainty. If data come in positive, the re-rating could come fast. The opposite is just as likely.

The Seeking Alpha author, who disclosed a long position, sees the risk/reward as favorable at current levels. The cash runway removes near-term financing risk. It does not protect against a failed trial. The readout is the only catalyst that matters for now.

For traders considering a position before the data, the key is sizing. The stock could gap up 100% or more on positive results. A failure could cut the valuation by half or more. The event has no announced date beyond the late Q2/early Q3 window. Timing the entry carries its own risk. Those who want to avoid the binary swing may wait until after the data. That might lose the asymmetric upside.

Alumis will hold a conference call shortly after the data release. The call will detail efficacy and the path to filing.